Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824489 | Clinical Therapeutics | 2016 | 20 Pages |
Abstract
This is the first patient-level meta-analysis, to our knowledge, to evaluate the efficacy in terms of Hb response of DA treatment when initiated according to current product labeling in patients with CIA. Limitations include the small number of studies and patients eligible for inclusion in the comparative analyses and the absence of non-Amgen trials of DA. The results of the comparative analysis confirm that DA is more effective than placebo at increasing serum Hb levels and at reducing the need for transfusion in patients with CIA when treatment is initiated at Hb â¤10 g/dL, as per current product labeling.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Robert MD, Michael MD, Johan MD, Enrique MD, Laura MSc, Jan-Henrik MD,